Yesid Alvarado Valero

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Phase II study of lower-intensity frontline therapy for newly diagnosed patients with AML who are unfit or otherwise not eligible for frontline clinical trials.”.

Phase II study of lower-intensity frontline therapy for newly diagnosed patients with AML who are unfit or otherwise not eligible for frontline clinical trials.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e19028

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Naveen Pemmaraju, Guillermo Montalban‐Bravo, Kelly S. Chien, Naval Daver +12 more

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood(2024)10.1182/blood-2024-211110

N/A

0DataRank · unranked

2 citations

Philip A. Thompson, Jan A. Burger, Musa Yılmaz, Nitin B. Jain, Tapan M. Kadia +23 more

Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Blood(2024)10.1182/blood-2024-209558

N/A

0DataRank · unranked

2 citations

Wei‐Ying Jen, Courtney D. DiNardo, Kelly S. Chien, Danielle Hammond, Yesid Alvarado Valero +12 more

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blood(2024)10.1182/blood-2024-203938

N/A

0DataRank · unranked

1 citations

Hagop M. Kantarjian, Musa Yılmaz, Naval Daver, Gautam Borthakur, Courtney D. DiNardo +15 more

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Blood(2024)10.1182/blood-2024-207413

N/A

0DataRank · unranked

1 citations

Jennifer Marvin‐Peek, Marina Konopleva, Gautam Borthakur, Naval Daver, Hussein A. Abbas +21 more

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Blood(2024)10.1182/blood-2024-210779

N/A

0DataRank · unranked

0 citations

Hussein A. Abbas, Guillermo Garcia‐Manero, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo +19 more

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Blood(2024)10.1182/blood-2024-205186

N/A

0DataRank · unranked

0 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado Valero +15 more